ResMed (RMD)
(Delayed Data from NYSE)
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
Genomic Health (GHDX) Oncotype DX GPS Test Results Positive
by Zacks Equity Research
Genomic Health's (GHDX) efforts to improve its prostate cancer business are encouraging.
IDEXX Laboratories Strong on CAG Business Amid Currency Woes
by Zacks Equity Research
IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.
Hill-Rom (HRC) Trades on Product Innovation, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation, the latest launch being Connex Cardio ECG.
Integra LifeSciences Global Prospects Solid, Competition Rife
by Zacks Equity Research
Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.
Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.
Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance
by Zacks Equity Research
Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.
Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)
by Zacks Equity Research
Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.
Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abaxis (ABAX) rides high on recently received approval from USDA.
ResMed (RMD) Rides on Product Launches, Robust Global Growth
by Zacks Equity Research
ResMed's (RMD) product launches and strategies to gain traction in the sleep-disordered breathing market. This upside is further likely to drive the stock in the future.
Intuitive Surgical Gains on FDA Approvals, Competition Rife
by Zacks Equity Research
Intuitive Surgical (ISRG) gains significantly on CE Mark approval for da Vinci X in Europe.
Hill-Rom (HRC) Beats Q1 Earnings and Revenues, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q1.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Abaxis (ABAX) Q3 earnings gain on strength in Medical and Veterinary segments.
Strength Seen in ResMed (RMD): Stock Soars 14.7%
by Zacks Equity Research
ResMed (RMD) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.
ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines
by Zacks Equity Research
ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.
Why Earnings Season Could Be Great for ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?
by Zacks Equity Research
ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.
ResMed (RMD) Rides on Innovation Amid Reimbursement Woes
by Zacks Equity Research
ResMed (RMD) achieves strong global revenue growth for the past few quarters on the back of sales of sleep devices, respiratory care devices, mask systems and software solutions.
Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report?
by Zacks Equity Research
ResMed (RMD) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?
by Zacks Equity Research
ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.
Why Is ResMed (RMD) Up 3.1% Since the Last Earnings Report?
by Zacks Equity Research
ResMed (RMD) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track
by Zacks Equity Research
ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.
Medical Products Earnings Due on Aug 1: IDXX, RMD
by Zacks Equity Research
There are some powerful long-term tailwinds of the medical device industry which have been a major driving force behind the sector's impressive performance over the past few quarters.
Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?
by Zacks Equity Research
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
Here's Why You Should Add ResMed to Your Portfolio Now
by Zacks Equity Research
California-based ResMed, Inc. (RMD) has been on a healthy growth trajectory of late.